文献速递胸部肿瘤乳腺癌消化系统肿瘤

2009—2013年珠江三角洲地区恶性肿瘤发病与死亡分析

[Cancer incidence and mortality in Pearl River Delta Area, 2009-2013].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2019-01-01

基于广州、深圳、中山、江门和四会5个肿瘤登记地区2009—2013年数据,估计珠江三角洲地区恶性肿瘤发病率为262.50/10万,中标率225.63/10万,世标率219.88/10万;死亡率为175.51/10万,中标率116.02/10万,世标率114.31/10万。发病前5位为女性乳腺癌、肺癌、结直肠癌、肝癌、鼻咽癌,死亡前5位为肺癌、肝癌、结直肠癌、女性乳腺癌、鼻咽癌。

要点

  • 珠江三角洲地区恶性肿瘤粗发病率为262.50/10万,中标率225.63/10万,世标率219.88/10万。
  • 粗死亡率为175.51/10万,中标率116.02/10万,世标率114.31/10万。
  • 发病前5位为女性乳腺癌、肺癌、结直肠癌、肝癌、鼻咽癌。

核心结论

  • 珠江三角洲地区恶性肿瘤负担较重,肺癌、结直肠癌、鼻咽癌、女性乳腺癌以及男性肝癌是主要癌种,应予以重点防治。

研究设计与样本

  • 基于2009—2013年广州、深圳、中山、江门和四会5个登记地区的肿瘤登记数据及相应人口数据,按性别和年龄分层估计发病率和死亡率。
  • 中标率采用2000年全国人口普查的标准人口年龄构成标化,世标率采用Segi's标准人口年龄构成标化。

主要发现

  • 2009—2013年恶性肿瘤粗发病率为262.50/10万,其中男性274.76/10万,女性249.49/10万。
  • 中标发病率为225.63/10万,世标发病率为219.88/10万。
  • 粗死亡率为175.51/10万,其中男性222.92/10万,女性127.46/10万。
  • 中标死亡率为116.02/10万,世标死亡率为114.31/10万。
  • 发病率在40岁以前处于较低水平,40岁以后快速上升尤其是男性,在80~84岁组达到发病高峰然后开始下降;死亡率在50岁以前处于较低水平,然后缓慢增高,在85岁及以上组达到高峰。

关键数值与推荐

  • 发病前5位依次是女性乳腺癌、肺癌、结直肠癌、肝癌、鼻咽癌。
  • 死亡前5位依次是肺癌、肝癌、结直肠癌、女性乳腺癌、鼻咽癌。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To estimate the incidence, mortality and characteristics of cancer in Pearl River Delta Area of Guangdong Province between 2009-2013. Methods: Based on five population-based cancer registration data from Guangzhou, Shenzhen, Zhongshan, Jiangmen and Sihui spanning from 2009 to 2013, along with those corresponding population data, the incidence and mortality rates were estimated by gender and age groups. Chinese standard population derived from the 2000 Population Census and Segi's standard population were used for age-standardized incidence and mortality rates. Results: Between 2009 and 2013, the crude cancer incidence rate was 262.50/100 000, 274.76/100 000 in male and 249.49/100 000 in female. After adjusting for Chinese and Segi's standard population, the age-standardized incidence rates were 225.63/100 000 and 219.88/100 000, respectively. The crude mortality rate was 175.51/100 000, 222.92/100 000 in male and 127.46/100 000 in female, respectively. After adjusting for Chinese and Segi's standard population, the age-standardized mortality rates were 116.02 /100 000 and 114.31/100 000, respectively. The incidence rates were at low levels in the population less than 40 years old, thereafter went up rapidly with age especially in male, and then reached the peak in the population aged 80 and above. As with incidence, the mortality rates kept at low levels in the population before their 50 s and then rose up steadily with age until peaking in the 85+ age group. The most common cancers were female breast cancer, lung cancer, colorectal cancer, liver cancer and nasopharyngeal cancer with descending incidence rate. Lung cancer, liver cancer, colorectal cancer, female breast cancer and nasopharyngeal cancer were the top five cancer-attributable causes of death. Conclusions: Currently, Pearl River Delta Area were faced with huge cancer burden. Lung cancer, colorectal cancer, nasopharyngeal cancer, female breast cancer and male liver cancer are predominant cancers and more efforts should be made to fight against them. 目的: 探讨2009—2013年珠江三角洲地区恶性肿瘤的发病和死亡水平及癌谱特征。 方法: 基于2009—2013年广东省广州、深圳、中山、江门和四会等5个登记地区的肿瘤登记数据,按照性别和年龄分层,结合2009—2013年的人口数据,估计珠江三角洲地区恶性肿瘤的发病率、死亡率及中国人口标化率(中标率)、世界人口标化率(世标率)等指标,其中中标率采用2000年全国人口普查的标准人口年龄构成进行标化,世标率采用Segi′s标准人口年龄构成进行标化,分析分性别、年龄的恶性肿瘤发病和死亡水平及顺位。 结果: 2009—2013年珠江三角洲地区恶性肿瘤发病率为262.50/10万(其中男性274.76/10万,女性249.49/10万),中标率为225.63/10万,世标率为219.88/10万。死亡率为175.51/10万(其中男性222.92/10万、女性127.46/10万),中标率为116.02/10万,世标率为114.31/10万。珠江三角洲地区恶性肿瘤发病率在40岁以前处于较低水平,40岁以后发病率快速上升,尤其是男性,发病率在80~84岁组达到发病高峰,然后开始下降。恶性肿瘤死亡率在50岁以前处于较低水平,然后缓慢增高,在85岁及以上组达到高峰。恶性肿瘤发病前5位依次是女性乳腺癌、肺癌、结直肠癌、肝癌、鼻咽癌,死亡前5位依次是肺癌、肝癌、结直肠癌、女性乳腺癌、鼻咽癌。 结论: 珠江三角洲地区恶性肿瘤负担较重,恶性肿瘤流行情况有其自身特点,肺癌、结直肠癌、鼻咽癌、女性乳腺癌以及男性肝癌是主要癌种,应予以重点防治。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xia L, Xu YJ, Xu XJ, et al. [Cancer incidence and mortality in Pearl River Delta Area, 2009-2013]. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31137176. doi:10.3760/cma.j.issn.0253-3766.2019.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。